WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407877

CAS#: 2003234-63-5 (R-isomer)

Description: R-GNE-140 a novel potent lactate dehydrogenase (LDHA) inhibitor with IC50 3nM for LDHA and 5 nM for LDHB. In MIA PaCa-2 human pancreatic cells, LDHA inhibition rapidly affected global metabolism, although cell death only occurred after 2 d of continuous LDHA inhibition. Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE-140, but could be resensitized to GNE-140 with the OXPHOS inhibitor phenformin. Acquired resistance to GNE-140 was driven by activation of the AMPK-mTOR-S6K signaling pathway, which led to increased OXPHOS, and inhibitors targeting this pathway could prevent resistance.

Price and Availability

Size Price Shipping out time Quantity
10mg USD 150 Same day
25mg USD 250 Same day
50mg USD 450 Same day
100mg USD 850 Same day
200mg USD 1550 Same day
500mg USD 2450 Same day
1g USD 3950 Same day
2g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-20. Prices are subject to change without notice.

R-GNE-140, purity > 98%, is in stock. The same day shipping after order received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 407877
Name: R-GNE-140
CAS#: 2003234-63-5 (R-isomer)
Chemical Formula: C25H23ClN2O3S2
Exact Mass: 498.0839
Molecular Weight: 499.04
Elemental Analysis: C, 60.17; H, 4.65; Cl, 7.10; N, 5.61; O, 9.62; S, 12.85

Related CAS #: 2003234-63-5 (R-isomer)   1809794-70-4 (racemic)    

Synonym: R-GNE-140; (R)-GNE-140; GNE 140; GNE140.

IUPAC/Chemical Name: (R)-3-((2-Chlorophenyl)thio)-4-hydroxy-6-(4-morpholinophenyl)-6-(thiophen-3-yl)-5,6-dihydropyridin-2(1H)-one


InChi Code: InChI=1S/C25H23ClN2O3S2/c26-20-3-1-2-4-22(20)33-23-21(29)15-25(27-24(23)30,18-9-14-32-16-18)17-5-7-19(8-6-17)28-10-12-31-13-11-28/h1-9,14,16,29H,10-13,15H2,(H,27,30)/t25-/m1/s1

SMILES Code: O=C1C(SC2=CC=CC=C2Cl)=C(O)C[C@](C3=CSC=C3)(C4=CC=C(N5CCOCC5)C=C4)N1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Metabolic reprogramming in tumors represents a potential therapeutic target. combining an LDHA inhibitor with compounds targeting the mitochondrial or AMPK-S6K signaling axis may not only broaden the clinical utility of LDHA inhibitors beyond glycolytically dependent tumors but also reduce the emergence of resistance to LDHA inhibition.


1: Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong
R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y,
Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson L, Vanderbilt
A, Williams S, Daemen A, Belvin M, Eigenbrot C, Jackson PK, Malek S,
Hatzivassiliou G, Sampath D, Evangelista M, O'Brien T. Metabolic plasticity
underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016
Oct;12(10):779-86. doi: 10.1038/nchembio.2143. Epub 2016 Aug 1. PubMed PMID: